-
Science & technology
Science & technology
Novavax creates transformational vaccines that help address some of the world’s most pressing infectious diseases.
- Overview
- Our pipeline
- Matrix-M™ adjuvant
- Recombinant, protein-based nanoparticle vaccine
- Global vaccine approval/authorization map
COVID-19 UPDATESNovavax has demonstrated its ability to quickly produce viable vaccine candidates for emerging infectious diseases such as COVID-19.
-
Who we are
Who we are
We are a biotechnology company committed to help address serious infectious disease globally through the discovery, development, and delivery of innovative vaccines to patients around the world.
Build your future with usJoin other passionately curious people who are bringing innovative vaccines to the world
-
Insights
Insights
Novavax is committed to accelerating the development of new and promising vaccines by building on years of study and experience.
COVID-19 press releases
After assessing safety and immunogenicity in phase 1/2 clinical trials, NVX-CoV2373 is currently in two pivotal phase 3 studies to evaluate vaccine efficacy, safety and immunogenicity.
NVX-CoV2373 clinical trials have enrolled more than 30,000 volunteers around the globe. Learn more about our clinical trial enrollment and progress toward diversity demographics.
Feb 13, 2023
COVID-19
U.S. Government and Novavax Extend Partnership, Securing Up to 1.5 Million Additional Doses of Novavax' COVID-19 Vaccine
Jan 27, 2023
Statement
COVID-19
Novavax Announces Plan to Deliver Updated Protein-based Vaccine Consistent with FDA Recommendations for 2023/2024 Vaccination Season at VRBPAC Meeting
Jan 18, 2023
COVID-19
Novavax Nuvaxovid COVID-19 Vaccine Approved in South Korea as an Adult Booster
Dec 30, 2022
COVID-19,Seasonal influenza
Novavax Announces Initiation of Phase 2 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza Vaccine Candidates
Dec 16, 2022
Statement
COVID-19
Global health
German Health Authority Expands Recommendation for Use of Novavax COVID-19 Vaccine as a Booster
Dec 7, 2022
COVID-19
Novavax Nuvaxovid COVID-19 Vaccine Approved in Canada for Use as a Primary Series in Adolescents
Nov 29, 2022
COVID-19
World Health Organization Updates Emergency Use Listing for Novavax Nuvaxovid COVID-19 Vaccine as a Primary Series in Adolescents and as a Booster in Adults
Nov 23, 2022
Statement
COVID-19
Termination of COVID-19 Vaccine Purchase Agreement with Gavi
Nov 18, 2022
COVID-19
Novavax Nuvaxovid COVID-19 Vaccine Receives Expanded Authorization in Canada as a Booster in Adults
Nov 9, 2022
COVID-19
Novavax Nuvaxovid™ COVID-19 Vaccine▼ Authorized in the United Kingdom for Use as a Booster in Adults
Highlights
Showper page